Skip to main content

Table 1 Transitional cell carcinoma of the bladder incidence and incidence-based mortality rates (1973–2014)

From: Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis

characteristic Incidence of bladder cancer Incidence-based mortality of bladder cancer
Cases, No (%)a Rate (95% CI)b Deaths, No (%)a Rate (95% CI)b
Overall 182,114 (100) 26.43 (26.55–26.31) 123,137(100) 18.68 (18.57–18.78)
Sex
 Male 136,897 (75.1) 47.21 (46.95–47.46) 92,733 (75.3) 37.70 (37.45–37.95)
 Female 45,217 (24.8) 11.48 (11.38–11.59) 30,404 (24.6) 7.41 (7.33–7.50)
Race
 Caucasian 166,426 (91.3) 28.77 (28.63–28.91) 113,599 (92.2) 20.13 (20.02–20.25)
 African American 7939 (4.3) 15.07 (14.73–15.41) 5493 (4.4) 11.92 (11.60–12.25)
 Othersc 6798 (3.7) 12.04 (11.75–12.34) 3866 (3.1) 7.72 (7.48–7.97)
Age at diagnosis, y
 20–44 5527 (3.0) 1.57 (1.53–1.62) 353 (0.4) 0.10 (0.09–0.12)
 45–64 50,194 (27.5) 21.01 (20.83–21.2) 10,369 (8.42) 4.25 (4.17–4.33)
 65–84 107,382 (58.9) 103.89 (103.27–104.51) 70,946 (57.6) 70.2 (69.68–70.72)
  > 84 19,011 (10.4) 134.61 (132.7–136.53) 41,469 (33.6) 293.62 (290.8–296.46)
State
 California 26,322 (14.4) 24.07 (23.78–24.37) 18,017 (14.6) 17.21 (16.96–17.47)
 Connecticut 33,844 (18.5) 32.3 (31.95–32.64) 22,862 (18.5) 21.99 (21.71–22.28)
 Georgia 10,954 (6) 22.29 (21.86–22.72) 6824 (5.5) 16.16 (15.77–16.55)
 Hawaii 5744 (3.2) 17.85 (17.39–18.32) 3650 (2.9) 11.99 (11.61–12.39)
 Iowa 26,254 (14.4) 26.95 (26.62–27.28) 18,888 (15.3) 18.34 (18.08–18.61)
 Michigan 33,036 (18.1) 29.51 (29.19–29.83) 22,985 (18.6) 21.98 (21.7–22.27)
 New Mexico 8838 (4.9) 19.88 (19.47–20.31) 5912 (4.8) 14.63 (14.26–15.01)
 Utah 8769 (4.8) 21.15 (20.71–21.60) 5689 (4.6) 15 (14.61–15.39)
 Washington 28,353 (15.5) 29.13 (28.79–29.48) 18,310 (14.8) 19.95 (19.66–20.24)
Stage at diagnosisd
 Localized 139,766 (76.7) 20.24 (20.14–20.35) 87,384 (70.9) 13.32 (13.24–13.41)
 Regional 31,612 (17.3) 4.62 (4.57–4.67) 26,214 (21.2) 3.93 (3.89–3.98)
 Distant 5174 (2.8) 0.75 (0.73–0 .77) 4922 (3.9) 0.72 (0.70–0.74)
Site
 Trigone 10,849 (5.8) 1.57 (1.54–1.60) 7030 (5.7) 1.07 (1.04–1.09)
 Dome 6176 (3.4) 0.91 (0.88–0.93) 4495 (3.7) 0.68 (0.66–0.70)
 Lateral wall 37,061 (20.4) 5.35 (5.29–5.40) 23,266 (18.9) 3.53 (3.49–3.58)
 Anterior wall 3112 (1.7) 0.46 (0.44–0.47) 2155 (1.8) 0.33 (0.31–0.34)
 Posterior wall 14,482 (8) 2.11 (2.08–2.15) 9199 (7.5) 1.40 (1.37–1.43)
 Neck 5478 (3.1) 0.8 (0.78–0.82) 3868 (3.1) 0.59 (0.57–0.61)
 Ureteric orifice 9709 (5.3) 1.39 (1.36–1.42) 6451 (5.2) 0.98 (0.96–1)
 Urachus 27 (0.01) 0.004 (0.003–0.006) 19 (0.01) 0.003 (0.002–0.005)
 Overlapping lesions 19,999 (11) 2.91 (2.87–2.96) 15,138 (12.3) 2.29 (2.25–2.32)
 Unknown 75,221 (41.3) 10.92 (10.84–11) 51,516 (41.8) 7.81 (7.74–7.88)
  1. a Cases included first primary tumors that matched the selection criteria, were microscopically confirmed, and were not identified only from autopsy records or death certificates
  2. b Rates were calculated as number of cases per 100,000 person-years and age adjusted to the 2000 US standard population
  3. c Includes American Indian/Alaskan Native and Asian/Pacific Islander
  4. d using SEER historic stage A